The company’s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patie...
The company’s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and autoimmune diseases.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.